The acceptance of Novocure's PMA application by the FDA is a significant regulatory milestone that suggests a positive outlook for the company's TTFields therapy. The clinical trial results demonstrating improved survival rates are likely to be viewed favorably by investors, as evidenced by the stock's sharp increase. The news directly impacts Novocure's potential revenue growth and market share in cancer treatment, hence the high relevance and importance. The confidence score reflects the current market reaction and the typical investor sentiment following such regulatory advancements.